2-(Cyclobutyloxy)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(Cyclobutyloxy)benzamide
• 英文别名: 2-cyclobutyloxybenzamide
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: ISQNVVMXBYPNCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP<br/>[FR] COMPOSÉS COMPRENANT UN GROUPE CYCLOBUTOXY
  申请人：UCB PHARMA SA

  公开号：WO2009147149A1

  公开（公告）日：2009-12-10

  The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals, useful for the treatment and prevention of diseases or pathological conditions of the central nervous system including mild-cognitive impairments, Alzheimer's disease, learning and; memory disorders, cognitive disorders, attention deficit disorder, attention-deficit hyperactivity disorder, Parkinson's disease, schizophrenia, dementia, depression, epilepsy, seizures, convulsions, sleep/wake and arousal/vigilance disorders such as hypersomnia and narcolepsy, pain and/or obesity.

  本发明涉及具有公式（I）的化合物，其中包括环丁氧基团，制备它们的方法，包含所述化合物的药物组合物以及它们作为药物的用途，适用于治疗和预防中枢神经系统的疾病或病理条件，包括轻度认知障碍、阿尔茨海默病、学习和记忆障碍、认知障碍、注意力缺陷障碍、注意力缺陷多动障碍、帕金森病、精神分裂症、痴呆、抑郁症、癫痫、癫痫发作、惊厥、睡眠/清醒和警觉/警觉障碍，如嗜睡症和睡病，以及疼痛和/或肥胖。
• [EN] 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS<br/>[FR] DERIVES D'ACIDE BENZHYDROXAMIQUE PHENYLAMINO 4-BROMO OU 4-IODO ET UTILISATION DE CES DERNIERS EN TANT QU'INHIBITEURS DE MEK
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1999001426A1

  公开（公告）日：1999-01-14

  (EN) Phenylamino benzhydroxamic acid derivatives of formula (I) where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.(FR) On décrit des dérivés d'acide benzhydroxamique phénylamino de formule (I). Dans la formule R1, R2, R3, R4, R5 et R6 représentent hydrogène ou des groupes substituants tels que alkyle; R7 représentant hydrogène ou un radical organique. Ces dérivés sont de puissants inhibiteurs de MEK et en tant que tels ils sont efficaces dans le traitement du cancer et d'autres maladies proliférantes telles que le psoriasis et la resténose.

  Phenylamino benzhydroxamic acid derivatives of formula (I) where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis. 翻译：公式（I）中的苯氨基苯甲酰羟肟酸衍生物，其中R1、R2、R3、R4、R5和R6是氢或取代基，例如烷基，而R7是氢或有机基团，是MEK的强效抑制剂，因此在治疗癌症和其他增生性疾病，如银屑病和再狭窄方面非常有效。
• Certain Chemical Entities, Compositions and Methods
  申请人：Qian Xiangping

  公开号：US20090306127A1

  公开（公告）日：2009-12-10

  Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

  本发明揭示了通过调节一个或多个有丝分裂动力蛋白的活性来治疗细胞增殖性疾病和疾病的化合物。
• Certain Chemical Entities, Compositions, and Methods
  申请人：Qian Xiangping

  公开号：US20090312365A1

  公开（公告）日：2009-12-17

  Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

  本发明涉及一种通过调节一个或多个有丝分裂动力蛋白的活性来治疗细胞增殖性疾病和障碍的化合物。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。